Affirmed Therapeutics BV (NASDAQ:AFMD) rose 1.8% during mid-day trading on Wednesday . The stock traded as high as $2.84 and last traded at $2.83, with a volume of 52,583 shares traded. The stock had previously closed at $2.78.

AFMD has been the subject of several recent analyst reports. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Affirmed Therapeutics BV in a research report on Wednesday, May 18th. Jefferies Group decreased their price objective on shares of Affirmed Therapeutics BV from $5.00 to $4.00 and set a “hold” rating for the company in a research report on Thursday, May 19th. Finally, Leerink Swann cut shares of Affirmed Therapeutics BV from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $8.00 to $3.00 in a research report on Friday, August 12th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $8.63.

The company’s market cap is $93.43 million. The company has a 50 day moving average of $2.81 and a 200 day moving average of $3.43.

Affirmed Therapeutics BV (NASDAQ:AFMD) last issued its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.05. The company had revenue of $2.07 million for the quarter, compared to analysts’ expectations of $2.10 million. During the same period last year, the business earned ($0.19) earnings per share. The business’s revenue was down 6.4% compared to the same quarter last year. Equities research analysts predict that Affirmed Therapeutics BV will post ($1.12) earnings per share for the current fiscal year.

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.